Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single- and multiple-ascending-dose study of ZP9830 in healthy participants
NL-OMON60580Phase 1Recruiting
- Sponsor
- Zealand Pharma
- Start
- Nov 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 1 trial of ZP9830 in autoimmune disease, sponsored by Zealand Pharma. Started Nov 2024; status: recruiting.
02
Drugs
ZP9830
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NL-OMON60580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60580.